लोड हो रहा है...
Second-Generation ALK Inhibitors: Filling the Non “MET” Gap
Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. The...
में बचाया:
| में प्रकाशित: | Cancer Discov |
|---|---|
| मुख्य लेखकों: | , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
2014
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4551422/ https://ncbi.nlm.nih.gov/pubmed/24891360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0410 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|